Ipca Laboratories credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
7047041,3021,3881,458
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−494−494194532−719
0.07×0.07×0.16×0.18×0.25×
−0.05×−0.05×0.02×0.07×−0.12×
0.36×0.36×0.75×1.05×1.57×
−0.22×−0.25×0.11×0.40×−0.78×
20.55×20.55×15.64×6.97×14.61×
6.9%6.9%13.4%15.2%19.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

IPCALAB₹1,926.20

Ipca Laboratories Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMJBCHEPHARMABBOTINDIAAJANTPHARMANTHEMGLAXOMEDANTAMcap ₹48,868 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt1,457.51,387.51,301.7703.9703.9
Net Debt-719.0532.3194.1-494.1-494.1
Total Debt/Equity0.250.180.160.070.07
Net Debt/Equity-0.120.070.02-0.05-0.05
Total Debt/EBITDA1.571.050.750.360.36
Net Debt/EBITDA-0.780.400.11-0.25-0.22
Interest Coverage (EBIT/Interest)14.616.9715.6420.5520.55
Total Debt/Total Capital %19.7715.2213.436.886.88
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.